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insulin results in renoprotection by reducing oxidative stress
in an earlier period, whereas PGZ does so by inhibiting
transforming growth factor-b production in a later period.3
The above-mentioned points need to be clarified before the
renoprotective effect of thiazolidinedione can be applied to
clinical practice in a large scale.
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Liu et al. are apparently concerned mainly with the
potential benefits of a combination of pioglitazone (PGZ)
and insulin treatment in type II diabetes mellitus. In
contrast, as stated in the introduction of our paper,1 we
evaluated whether, despite similar or even worse glucose
levels, renoprotection achieved by PGZ monotherapy (and
its attendant correction of hyperinsulinemia) differed from
that obtained with insulin alone. We did not include,
therefore, a group treated with both insulin and PGZ. In
parenthesis, in a recent review article, Sarafidis and Bakris2
summarized all human clinical and experimental animal
studies relevant to the renoprotective benefits of thiazoli-
dinediones: only 1 out of 29 studies allowed the use of
insulin in combination with thiazolidinediones.
For similar reasons, creatinine clearance was evaluated
only at the end of the study, as we were not interested in a
PGZ–insulin combined treatment.
We agree with Liu et al. that higher PGZ doses might
have further improved glucose control, but a search for a
maximal effect on glucose was beyond the rationale of our
study.
Liu et al. speculate on the transient effect of insulin on
proteinuria. We are unable to comment their hypothesis as
our study was not designed to assess this issue. We should
point out, however, that, contrary to the statement by Liu
et al., Schena and Gesualdo3 do not consider the effect of
insulin treatment on renal oxidative stress.
Our findings demonstrate only that, in a type II diabetic
rat model, PGZ monotherapy improves renoprotection
above that obtained by insulin alone. We speculate that
this benefit is due to fall in circulating insulin levels,
probably through a reduction of transforming growth
factor-b expression. We wholeheartedly agree with Liu
et al. that extension of our conclusions to human disease
requires further clinical studies. In this context, they will
be interested to learn that, in Japan only, a large clinical
study is already in progress based on the potential clinical
benefit of thiazolidinediones in type II diabetics, that is,
the Japan Diabetes Outcome Intervention Trial (3000
patients are to be enrolled),4 and another clinical study is
in the planning stage based on the clinical benefit of PGZ
in type II diabetics, that is, Pioglitazone Multicenter
Intervention Clinical Trial in Hospital of Tohoku Region
Improving Nephropathy, Oxidative Stress, Kidney Injury,
Urinary Albumin Excretions study (200 patients; S Ito,
personal communication).
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To the Editor: The article ‘Early steroid treatment improves
the recovery of renal function in patients with drug-induced
acute interstitial nephritis’ has great significance in clinical
practice but needs to be interpreted with caution.1
In this multicenter retrospective analysis the role of
steroids in patients with biopsy-proven drug-induced acute
interstitial nephritis was evaluated in 61 patients. The authors
found that final serum creatinine values in patients who were
treated with steroids, especially early in the course of disease
were significantly lower than the untreated group. In this
study patients were categorized as mild, moderate, and severe
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based on histology. Although the proportion of patients in
each group is statistically similar, the group which had not
received steroids comprises only nine patients and 89.5% of
the patients who received steroids early had only a mild
degree of interstitial fibrosis compared to 30% in the group
which received late steroid therapy.
In a retrospective analysis of 60 cases of biopsy-proven
drug-induced acute interstitial nephritis, Clarkson et al.2 did
not observe any difference in outcome of patients in relation
to steroid treatment. Number of cases in each group was
comparable and both the groups had similar histology.
Although controversial, histological severity has previously
been noted as a major prognostic factor.3 Further, physicians
have a different threshold for performing a kidney biopsy in
cases suspected to be related to drug-induced acute
interstitial nephritis and early withdrawal of the offending
drug may bias the physician to not perform a biopsy. Thus
there may be many more cases of drug-induced acute
interstitial nephritis who would recover without steroid
treatment and biopsy. This is amply highlighted by the fact
that the authors could only trace 61 cases of biopsy proven
acute interstitial nephritis over a period of 31 years
(1975–2006) from 10 centers. Finally it would only seem
natural for the cases with very poor histology to not have
been considered for steroid treatment.
We conclude by saying that besides early withdrawal of the
offending drug, histology may be an important determinant
of outcome. The role of steroids in drug-induced interstitial
nephritis will remain a mystery.
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Khaira and Mendoca criticize the conclusions of our study1
on the basis of its histologic findings. They point out that a
mild degree of interstitial fibrosis was more frequently
found in renal biopsies of patients who completely
recovered their baseline renal function (Group 1a) than
in patients with an incomplete recovery (Group 1b) (89.3
versus 29.2%). The authors conclude that there may be
many more cases of drug-induced acute interstitial
nephritis (DI-AIN) that would recover without steroid
treatment and performance of renal biopsy. We think, on
the contrary, that the histologic findings of our study
reinforce our conclusions. Khaira and Mendoca do not
realize that the interval between drug withdrawal and
renal biopsy performance was significantly shorter in
Group 1a than in Group 1b (13±10 versus 33±17 days).
This is a crucial difference because we think that the more
advanced degree of interstitial fibrosis in Group 1b
patients is a consequence of the delay in the performance
of renal biopsies, which were always performed before the
onset of steroid treatment. Our data strongly suggest that a
delay in the onset of steroid treatment allows the rapid
replacement of interstitial infiltrates by areas of fibrosis.
This histologic evolution is clearly exemplified by those
patients of our study in whom a second renal biopsy was
performed several weeks after the first one: the large
interstitial infiltrates of the first biopsy had been largely
replaced by areas of fibrosis.
The authors also comment on the results of Clarkson’s
study,2 in which no differences in the outcome of patients
with DI-AIN in relation to steroid treatment were
observed. However, it is important to remark that in
Clarkson’s study steroid treatment was considerably
delayed in most of the patients. As our data show, the
effectiveness of steroids in DI-AIN depends on its
precocity: the outcome of patients who did not receive
steroids was very bad, but those patients in whom steroids
were introduced several weeks after the withdrawal of the
offending drug had also a poor outcome in comparison
with patients who received steroids early after diagnosis of
DI-AIN.
We agree that some patients with DI-AIN can recover
their baseline renal function after the withdrawal of the
offending agent without steroids. The problem is that
there are no available markers that allow conclusively the
identification of these cases and the prediction of a
favorable evolution. In fact, most patients with DI-AIN
show an initial serum creatinine decrease after the
withdrawal of the offending drug and in the absence of
steroids, as our study also illustrates. Nevertheless, this
initial improvement is followed by a stop in serum
creatinine decrease in many cases, leaving the patient with
different degrees of irreversible chronic renal insufficiency.
Our study clearly indicates that a short course of steroids
significantly decreases the risk of chronic renal insuffi-
ciency after an episode of DI-AIN.
Finally, we think that the results of our study are
applicable to those patients with acute renal failure in
whom a diagnosis of DI-AIN seems firm on clinical
grounds (chronologic relationship with a drug, fever, skin
rash, eosinophilia) but the performance of a renal biopsy is
contraindicated by different reasons. Although the pub-
lished information about the management of such patients
is very limited, our current clinical practice is to promptly
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